This is the first step in its development project which will allow it to offer its customers a more complete and quality portfolio with improved biological and pharmacological services.
The site will be called the Guy Ourisson Research Campus and will be shared by several users:
• NovAliX, with its main headquarters and its scientific center for the provision of research services
• The Institute of Biophysics for Biomedical Research (IBRB), a center co-founded with an academic group, which focuses on medical innovation resulting from advances in electronic cryo-microscopy
• The Biotech Factory, made up of laboratories dedicated to therapeutic innovation used by several biotechnology companies
“Our main objective was to find a buyer capable of maintaining very high standards of quality biomedical research. NovAliX ticked all the boxes on our list, ”said Jacques Volckmann, France R&D manager at Sanofi. “I am delighted to see NovAliX further develop its activity in Strasbourg following this takeover and to see it become a key player in the local ecosystem with its international ambition. Sanofi will also benefit from the expertise of the NovAliX teams – with a partnership announced at the end of 2021, through which we are currently working together to develop new DNA -encoded libraries.
“By acquiring this site, NovAliX has the opportunity to accelerate its development, to exploit new biological and pharmacological capacities, and thus to strengthen its position as CRO and to become an essential and valuable partner, contributing to the success of research therapy of its clients. programs, ”said Stephan Jenn, president and co-founder of NovAliX. “This transaction also represents an opportunity for the founders of the company to bring our vision of the future of research to life. This campus acts as a manifesto, it promises a new way of organizing discovery research and offers a unique place, bringing together stakeholders to promote the emergence and success of therapeutic innovation.
The Institute of Biophysics for Biomedical Research is a project that brings together NovAliX and a world-renowned academic group. It is not only a technological platform offering electronic cryomicroscopy at the highest level, but also a place dedicated to the creation of new therapeutic options and technologies.
The construction program, led by Guillaume Delemazure of DeA architectes, will start in 2022 and will transform the site on campus; it will be appropriately equipped for any activity that is to take place.